JP2024546026A5 - - Google Patents
Info
- Publication number
- JP2024546026A5 JP2024546026A5 JP2024527503A JP2024527503A JP2024546026A5 JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5 JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ala
- approximately
- ile
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111341752 | 2021-11-12 | ||
| CN202111341752.0 | 2021-11-12 | ||
| PCT/CN2022/131375 WO2023083301A1 (zh) | 2021-11-12 | 2022-11-11 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546026A JP2024546026A (ja) | 2024-12-17 |
| JP2024546026A5 true JP2024546026A5 (cg-RX-API-DMAC7.html) | 2025-11-11 |
Family
ID=86335124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527503A Pending JP2024546026A (ja) | 2021-11-12 | 2022-11-11 | Glp-1受容体及びgip受容体二重アゴニストの医薬組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250115654A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4431522A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546026A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240109258A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118103391A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022386489A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237796A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005663A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202333773A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023083301A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| WO2025124473A1 (zh) | 2023-12-12 | 2025-06-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物治疗代谢疾病的方法及医药用途 |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025252197A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏恒瑞医药股份有限公司 | 药物组合物 |
| TW202611066A (zh) * | 2024-08-16 | 2026-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Glp-1類似物的醫藥用途 |
| WO2026092429A1 (zh) * | 2024-10-28 | 2026-05-07 | 江苏恒瑞医药股份有限公司 | 药物递送组合物 |
| WO2026153399A1 (zh) * | 2025-01-15 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | 一种药物组合物 |
| WO2026153411A1 (zh) * | 2025-01-20 | 2026-07-23 | 江苏豪森药业集团有限公司 | 一种双重激动剂的药物组合物、制备方法及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
| RU2013133803A (ru) * | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| CA2872314C (en) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| HUE035803T2 (en) * | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| JP7250706B2 (ja) * | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| MY206306A (en) * | 2018-10-26 | 2024-12-07 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| AU2020256648B2 (en) * | 2019-04-11 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| WO2021053578A1 (en) * | 2019-09-19 | 2021-03-25 | Dr. Reddy’S Laboratories Limited | Improved purification processes for liraglutide |
| AU2020418207A1 (en) * | 2019-12-30 | 2022-08-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting GLP-1 compound |
| CN118754965A (zh) * | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
-
2022
- 2022-11-11 CN CN202280069025.XA patent/CN118103391A/zh active Pending
- 2022-11-11 EP EP22892094.8A patent/EP4431522A4/en active Pending
- 2022-11-11 TW TW111143259A patent/TW202333773A/zh unknown
- 2022-11-11 US US18/709,004 patent/US20250115654A1/en active Pending
- 2022-11-11 JP JP2024527503A patent/JP2024546026A/ja active Pending
- 2022-11-11 MX MX2024005663A patent/MX2024005663A/es unknown
- 2022-11-11 CA CA3237796A patent/CA3237796A1/en active Pending
- 2022-11-11 WO PCT/CN2022/131375 patent/WO2023083301A1/zh not_active Ceased
- 2022-11-11 KR KR1020247018683A patent/KR20240109258A/ko active Pending
- 2022-11-11 AU AU2022386489A patent/AU2022386489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7461997B2 (ja) | 制御放出および持続的放出のためのelp融合タンパク質 | |
| US7939494B2 (en) | Method for administering GLP-1 molecules | |
| WO2021136296A1 (zh) | 胰岛素衍生物 | |
| JP2024170428A (ja) | グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用 | |
| JP2006520818A (ja) | ポリエチレングリコール結合glp−1化合物 | |
| JP2023526973A5 (cg-RX-API-DMAC7.html) | ||
| CA2708762A1 (en) | Formulation of insulinotropic peptide conjugates | |
| JP2006520818A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546026A (ja) | Glp-1受容体及びgip受容体二重アゴニストの医薬組成物及びその使用 | |
| JP2011506442A5 (cg-RX-API-DMAC7.html) | ||
| WO2011109784A1 (en) | Formulation of insulinotropic peptide conjugates | |
| WO2011109787A1 (en) | Methods of administering insulinotropic peptides | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| WO2023143458A1 (zh) | 酰化胰岛素 | |
| CN119386161A (zh) | 用fgf21变体治疗代谢障碍的方法 | |
| TW202227123A (zh) | 一種包含人白細胞介素2變體或其衍生物的醫藥組成物及其用途 | |
| WO2025185605A1 (en) | Polypeptide conjugates and methods of uses | |
| EA053272B1 (ru) | Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение | |
| HK1166449B (en) | Method for administering glp-1 molecules |